5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis

PHASE3CompletedINTERVENTIONAL
Enrollment

631

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

January 24, 2023

Study Completion Date

January 24, 2023

Conditions
Actinic Keratosis
Interventions
DEVICE

Solcera

Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)

DEVICE

Placebo

Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)

DRUG

Solaraze

Twice daily application for a duration of 60 days

Trial Locations (18)

14612

Hautarztpraxis Falkensee, Falkensee

30159

Praxis Dres. Med. Markus Kaspari und Florian Schenk, Hanover

41061

Zentderma GBR, Mönchengladbach

42287

Centroderm GmbH, Wuppertal

42349

Hautzentrum Wuppertal, Wuppertal

49809

Praxis Dres. K.-H. Vehring/U. Amann, Lingen

50996

Hautzentrum Köln, Cologne

53111

MVZ - Dermatologisches Zentrum Bonn GmbH, Bonn

65812

Hautmedizin Bad Soden, Bad Soden

94474

Hautarztpraxis Vilshofen, Vilshofen

Unknown

Proderma Studienzentrum, Dülmen

Hautzentrum Südbaden, Freiburg im Breisgau

Hautarztzentrum Hamm, Hamm

Durani Cosmetics GmbH, Heidelberg

Hautarztpraxis Ibbenbüren, Ibbenbueren

Haut- und Laserzentrum, Potsdam

Hautarztpraxis Asefi/Sadjadi, Simmern

Hautarztpraxis Leitz und Kollegen, Stuttgart

All Listed Sponsors
collaborator

Gesellschaft für Therapieforschung mbH

INDUSTRY

lead

Infectopharm Arzneimittel GmbH

INDUSTRY

NCT04552327 - 5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis | Biotech Hunter | Biotech Hunter